You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
An Open-Source Platform for Inter-Network Analytics of High-Consequence Events
SBC: ANOMALEE INC. Topic: DTRA14B003Objectives and Intellectual Merit: The infrastructure of modern civilization is a set of complex systems1 that dynamically interact across multiple layers of abstraction. Researchers from many disciplines2 are designing analytical tools for predicting the global and local behaviors of these complicated, multi-layer networks. Easily usable, available (open source) and inter-operated tools are neede ...
STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency -
A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation
SBC: CFD RESEARCH CORPORATION Topic: DTRA14B004Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is critical to detect the proliferation of nuclear material. Critical challenges facing this objective include: (a) high sensitivity detection of signature emissions (e.g., gamma rays) from common radioactive isotopes behind shielding, and (b) cost-effe ...
STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GeneCapture, Inc. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Modular Pulse Charger and Laser Triggering System for Large-Scale EMP and HPM Applications
SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC. Topic: DTRA16A004For effective protection against EMP and HPM threats, it is important to understand the physics of the threats, and also to quantify the effects they have on electrical systems. EMP and HPM vulnerability testing requires delivery of high peak power and electric fields to distant targets. The most practical solution to simulate such environments is to develop a modular, optically-isolated MV-antenn ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Development of powder bed printing (3DP) for rapid and flexible fabrication of energetic material payloads and munitions
SBC: MAKEL ENGINEERING INC Topic: DTRA16A001This program will demonstrate how additive manufacturing technologies can be used with reactive and high energy materials to create rapid and flexible fabrication of payload and munitions. Our primary approach to this problem will be to use powder bed binder printing techniques to print reactive structures. The anticipated feedstock will consist of composite particles containing all reactant spe ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus
SBC: EVRYS BIO LLC Topic: CBD18A002In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense